전체메뉴
검색
Article Search

JMB Journal of Microbiolog and Biotechnology

QR Code QR Code

Research article

References

  1. Heegaard PM, Miller I, Sorensen NS, Soerensen KE, Skovgaard K. 2013. Pig alpha1-acid glycoprotein: characterization and first description in any species as a negative acute phase protein. PLoS One 8: e68110.
    Pubmed PMC
  2. Schmid K, Nimerg RB, Kimura A, Yamaguchi H, Binette JP. 1977. The carbohydrate units of human plasma alpha1-acid glycoprotein. Biochim. Biophys. Acta 492: 291-302.
  3. Hochepied T, Berger FG, Baumann H, Libert C. 2003. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 14: 25-34.
  4. Bteich M. 2019. An overview of albumin and alpha-1-acid glycoprotein main characteristics: highlighting the roles of amino acids in binding kinetics and molecular interactions. Heliyon 5: e02879.
    Pubmed PMC
  5. Kwon H, Pessin JE. 2013. Adipokines mediate inflammation and insulin resistance. Front. Endocrinol. (Lausanne) 4: 71.
    Pubmed PMC
  6. Lumeng CN, Saltiel AR. 2011. Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 121: 2111-2117.
    Pubmed PMC
  7. Bachtiar I, Santoso JM, Atmanegara B, Gani RA, Hasan I, Lesmana LA, et al. 2009. Combination of alpha-1-acid glycoprotein and alpha-fetoprotein as an improved diagnostic tool for hepatocellular carcinoma. Clin. Chim. Acta 399: 97-101.
    Pubmed
  8. Ohbatake Y, Fushida S, Tsukada T, Kinoshita J, Oyama K, Hayashi H, et al. 2016. Elevated alpha1-acid glycoprotein in gastric cancer patients inhibits the anticancer effects of paclitaxel, effects restored by co-administration of erythromycin. Clin. Exp. Med. 16: 585592.
    Pubmed PMC
  9. Katnik I, Gerber J, Dobryszycka W. 1988. Microheterogeneity of alpha 1-acid glycoprotein in the sera of patients with cancer or inflammatory states of the ovaries. Arch. Immunol. Ther. Exp. (Warsz) 36: 1-6.
  10. Piver MS, Moyer M, Diakun K, Lele SB, Chu TM. 1988. Serum alpha 1-acid glycoprotein in epithelial ovarian cancer. Gynecol. Oncol. 29: 305-308.
  11. Fernandes CL, Ligabue-Braun R, Verli H. 2015. Structural glycobiology of human alpha1-acid glycoprotein and its implications for pharmacokinetics and inflammation. Glycobiology 25: 1125-1133.
    Pubmed
  12. Nakano M, Kakehi K, Tsai MH, Lee YC. 2004. Detailed structural features of glycan chains derived from alpha1-acid glycoproteins of several different animals: the presence of hypersialylated, O-acetylated sialic acids but not disialyl residues. Glycobiology 14: 431-441.
    Pubmed
  13. Zhang D, Huang J, Luo D, Feng X, Liu Y, Liu Y. 2017. Glycosylation change of alpha-1-acid glycoprotein as a serum biomarker for hepatocellular carcinoma and cirrhosis. Biomark. Med. 11: 423-430.
    Pubmed
  14. Hashimoto S, Asao T, Takahashi J, Yagihashi Y, Nishimura T, Saniabadi AR, et al. 2004. alpha1-acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis. Cancer 101: 2825-2836.
    Pubmed
  15. Balmana M, Gimenez E, Puerta A, Llop E, Figueras J, Fort E, et al. 2016. Increased alpha1-3 fucosylation of alpha-1-acid glycoprotein (AGP) in pancreatic cancer. J. Proteomics 132: 144-154.
    Pubmed
  16. Yazawa S, Takahashi R, Yokobori T, Sano R, Mogi A, Saniabadi AR, et al. 2016. Fucosylated glycans in alpha1-acid glycoprotein for monitoring treatment outcomes and prognosis of cancer patients. PLoS One 11: e0156277.
    Pubmed PMC
  17. Organization WH. 2019. Breast cancer. https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/.
  18. Youlden DR, Cramb SM, Yip CH, Baade PD. 2014. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol. Med. 11: 101-115.
  19. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. 2007. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25: 5287-5312.
    Pubmed
  20. Saldova R, Asadi Shehni A, Haakensen VD, Steinfeld I, Hilliard M, Kifer I, et al. 2014. Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC. J. Proteome Res. 13: 2314-2327.
    Pubmed
  21. Chan J, Yu D. 1991. One-step isolation of alpha 1-acid glycoprotein. Protein Exp. Purif. 2: 34-36.
  22. Kim HJ, Lim SJ, Kwag HL, Kim HJ. 2012. The choice of resin-bound ligand affects the structure and immunogenicity of columnpurified human papillomavirus type 16 virus-like particles. PLoS One 7: e35893.
    Pubmed PMC
  23. Park MH, You JW, Kim HJ, Kim HJ. 2019. IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation. J. Microbiol. 57: 821-827.
    Pubmed
  24. Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. 2017. Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA. Cancer J. Clin. 67: 290-303.
    Pubmed
  25. Durham M, Regnier FE. 2006. Targeted glycoproteomics: serial lectin affinity chromatography in the selection of O-glycosylation sites on proteins from the human blood proteome. J. Chromatogr. A. 1132: 165-173.
    Pubmed
  26. Choi JW, Moon BI, Lee JW, Kim HJ, Jin Y, Kim HJ. 2018. Use of CA153 for screening breast cancer: An antibodylectin sandwich assay for detecting glycosylation of CA153 in sera. Oncol. Rep. 40: 145-154.
  27. Stowell SR, Ju T, Cummings RD. 2015. Protein glycosylation in cancer. Annu. Rev. Pathol. 10: 473-510.
    Pubmed PMC
  28. Hulsmeier AJ, Paesold-Burda P, Hennet T. 2007. N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry. Mol. Cell Proteomics 6: 2132-2138.
    Pubmed
  29. Lee CS, Taib NA, Ashrafzadeh A, Fadzli F, Harun F, Rahmat K, et al. 2016. Unmasking heavily O-Glycosylated serum proteins using perchloric acid: identification of serum proteoglycan 4 and protease C1 inhibitor as molecular indicators for screening of breast cancer. PLoS One 11: e0149551.
    Pubmed PMC
  30. Kremer JM, Wilting J, Janssen LH. 1988. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev. 40: 1-47.
  31. McCurdy TR, Bhakta V, Eltringham-Smith LJ, Gataiance S, Fox-Robichaud AE, Sheffield WP. 2011. Comparison of methods for the purification of alpha-1 acid glycoprotein from human plasma. J. Biomed. Biotechnol. 2011: 578207.
    Pubmed PMC
  32. Mackiewicz A, Mackiewicz K. 1995. Glycoforms of serum alpha 1-acid glycoprotein as markers of inflammation and cancer. Glycoconj. J. 12: 241-247.
    Pubmed
  33. Pos O, Oostendorp RA, van der Stelt ME, Scheper RJ, Van Dijk W. 1990. Con A-nonreactive human alpha 1-acid glycoprotein (AGP) is more effective in modulation of lymphocyte proliferation than Con A-reactive AGP serum variants. Inflammation 14: 133-141.
    Pubmed
  34. Shiyan SD, Bovin NV. 1997. Carbohydrate composition and immunomodulatory activity of different glycoforms of alpha1-acid glycoprotein. Glycoconj. J. 14: 631-638.
    Pubmed
  35. Bories PN, Guenounou M, Feger J, Kodari E, Agneray J, Durand G. 1987. Human alpha 1-acid glycoprotein-exposed macrophages release interleukin 1 inhibitory activity. Biochem. Biophys. Res. Commun. 147: 710-715.

Related articles in JMB

More Related Articles